Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477539 · ClinicalTrials.gov registry record · Phase 2
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03477539: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03477539 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477539, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Daratumumab
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477539
The ClinicalTrials.gov registry entry for NCT03477539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT03477539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03477539 about?
NCT03477539 is a clinical study titled "Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma". This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
What is the current status of trial NCT03477539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-04-09. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT03477539?
The interventions under investigation include: Lenalidomide (DRUG), Daratumumab (BIOLOGICAL), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03477539?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.